Pinealon Peptide: Research Overview, Purity Data and Where

Most of what circulates online about Pinealon comes from vendor copy rather than from the indexed scientific record. The real literature is narrower, older and more specific than the marketing around it: a three-amino-acid peptide examined mainly in cell culture and rodent models of oxidative stress and hypoxia.

We read certificates of analysis for a living, and that shapes how we write about any compound in this category. All products are sold for laboratory research use only and are not for human consumption.

What is Pinealon?

Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg (EDR) and a calculated molecular weight of roughly 418.4 daltons. It belongs to the short regulatory peptide class studied by Russian gerontology groups. Pinealon is a research chemical supplied as a lyophilised powder for laboratory use, not an approved drug product.

The common over-simplification is that Pinealon is a pineal gland extract. It is not. Pinealon is chemically synthesised, sequence-defined and contains no glandular material of any kind. This page covers the mechanism the literature proposes, what published studies actually examine, laboratory handling and storage, how per-lot purity is documented, and what to verify before you buy Pinealon for research.

What the molecule actually is

Pinealon is built from three amino acids in a fixed order: glutamic acid, aspartic acid and arginine, written Glu-Asp-Arg and abbreviated EDR. The molecular formula is C15H26N6O8, the calculated mass sits near 418.4 daltons, and the compound presents as a white to off-white lyophilised powder that is freely soluble in water. Many catalogues list it under EDR rather than the trade-style name, which is the first place confusion starts.

Classification matters more than branding here. Pinealon sits inside the short regulatory peptide group sometimes called peptide bioregulators or cytogens, a research category developed from the 1980s onward. It gets confused constantly with Epitalon, which is a completely different molecule: a tetrapeptide, Ala-Glu-Asp-Gly. Same research lineage, different sequence, different body of work.

The proposed mechanism deserves careful hedging. The literature describes very short peptides as small enough to cross cell and nuclear membranes without a dedicated transporter, and suggests they may interact with DNA and chromatin in a sequence-selective way that influences transcription rather than engaging a classical surface receptor. That framing is a hypothesis built on preclinical work. No receptor for Pinealon has been characterised the way, say, the GLP-1 receptor has been.

Our team has reviewed a great many certificates across this category, and the most common procurement failure isn't low purity. It's the wrong molecule. A 99% HPLC purity figure describes how clean the dominant peak is. It says nothing about whether that peak is EDR. Purity and identity are separate assays, and only mass spectrometry answers the second question.

What the published literature examines

The indexed research on Pinealon is preclinical, modest in volume, and concentrated in a small number of laboratories. The searchable record can be reviewed directly on PubMed and cross-checked under the sequence term Glu-Asp-Arg, which surfaces papers that never use the trade-style name at all.

The recurring themes are consistent. Studies report work in neuronal cell cultures exposed to oxidative stress or oxygen deprivation, measurements of apoptosis markers, behavioural and cognitive testing in rodent models including prenatal hypoxia paradigms, and assays of gene and protein expression. Research in this area suggests the peptide may influence markers associated with cell survival under stress conditions. That is the honest ceiling of what the record supports.

Three limitations are worth stating plainly. First, a large share of Pinealon publications trace back to a single research school, which weakens independent replication. Second, sample sizes in preclinical work of this type are typically small. Third, there are no large registered human trials, so Pinealon has no established clinical profile and is not an approved therapy in any jurisdiction.

Researchers who contact us about Pinealon almost always arrive with a defined model already chosen, usually a neuroprotection or oxidative stress assay, rather than general curiosity. That pattern tells you something about who the compound is genuinely useful to. If you are reading a vendor page that describes outcomes in people, you have left the evidence base entirely and entered advertising.

Laboratory handling and storage basics

Lyophilised short peptides are stable compounds when kept dry, cold and dark. Standard laboratory practice for a powder like Pinealon is storage at minus 20 degrees Celsius or below, desiccated, protected from light, with the container sealed against ambient moisture. The lyophilised form tolerates short ambient periods during transit far better than an aqueous solution does, which is why carriers can move these materials without cold chain packaging.

Two handling details matter more than people expect. Let a frozen vial equilibrate to room temperature before opening it, because condensation introduces water into a hygroscopic powder and water is what drives degradation. And once a peptide is in aqueous solution, chemical stability drops sharply: short-term refrigerated storage at 2 to 8 degrees Celsius, aliquoted to avoid repeated freeze-thaw cycles, is the conventional approach in research settings.

Sequence chemistry adds a specific caveat for this molecule. Peptides containing aspartic acid are known to be susceptible to aspartimide formation and backbone rearrangement, particularly at unfavourable pH, and Pinealon carries an Asp residue in the middle of a three-residue chain. That is a degradation pathway no visual inspection will reveal. A powder that looks perfect can still have drifted from spec.

One boundary we hold firmly: Real Peptides does not provide preparation, measurement or administration guidance, because these are research-use-only compounds and that guidance would imply a use we do not support. The only arithmetic we will discuss is concentration, meaning the mass of peptide stated on the certificate divided by the volume of solvent, expressed as mg per mL. Study parameters belong to the study that ran them.

How per-lot purity is actually verified

A certificate of analysis is only meaningful if it describes the exact material in your hand. For Pinealon, a complete certificate should carry the lot number printed on the vial, a test date, the analysing method, an HPLC chromatogram with a stated purity percentage, and a mass spectrometry result confirming the observed mass matches the calculated value for Glu-Asp-Arg. Appearance and water content commonly appear alongside those two core assays.

The chromatogram is the part most buyers never ask for, and it is the part that carries the information. A purity figure typed onto a product page is an assertion. A chromatogram showing a single dominant peak with a stated retention time is evidence. Those are not the same category of claim, and in a research setting the difference determines whether your results are attributable to the compound or to an impurity profile nobody characterised.

Real Peptides works from small-batch synthesis with exact amino-acid sequencing and publishes certificates for the material it supplies, which you can review on the certificates of analysis page rather than taking a marketing sentence at face value. Our approach to documentation across the catalogue is set out on our pure peptides page. We mean this sincerely: documentation you cannot inspect before purchase is documentation that does not exist.

The red flags are easy to spot once you know them. An undated certificate. A certificate with no lot number. The same PDF attached to multiple products. A purity claim with no named analytical method. Any one of those should stop a procurement decision, not slow it down.

Regulatory status and ordering Pinealon for research use

Pinealon is not an FDA-approved drug product, not a dietary supplement, and not a compounded medication. It occupies the research chemical category, which means it is manufactured and sold for in vitro and preclinical laboratory investigation by qualified researchers and institutions. It carries no approved indication anywhere, and no regulatory body has evaluated it for human safety or efficacy. The information here is educational and describes published research, not guidance for any person.

That status drives how legitimate suppliers write. A compliant Pinealon listing describes the compound, its sequence, its mass, its documentation and its research context. It never describes what the compound will do for the person reading. If a supplier's Pinealon page includes usage instructions or health outcomes, the regulatory problem is theirs, but the data integrity risk becomes yours.

When procuring, three checks cover most of the risk. Confirm the molecular identity data matches Glu-Asp-Arg. Confirm the certificate's lot number matches the vial. Confirm the research-use-only terms are stated on the listing, the label and at checkout rather than buried in a footer.

Real Peptides supplies Pinealon as a catalogue compound for laboratory research, and the specifications and current availability sit on the Pinealon product page alongside the rest of our research compounds in the full peptide catalogue, with lot documentation collected in the COA library. All products are sold for laboratory research use only and are not for human consumption.

Pinealon Sourcing: Supplier Verification Comparison

The practical question for most buyers isn't whether Pinealon is interesting, it's whether a given vial matches its label. These four checkpoints separate documented suppliers from catalogue resellers.

What If: Laboratory Procurement and Handling Scenarios

What if the vial arrives at ambient temperature?

Inspect the powder and the seal, then move the vial to frozen storage and log the transit conditions. Lyophilised peptides are considerably more thermally forgiving than solutions, and short ambient periods during shipping are standard across the industry, which is why cold chain packaging is not routine for dry powders. The risk is not a few warm days in transit. The risk is moisture ingress through a compromised seal, because water is the variable that drives hydrolysis and aspartimide formation in Asp-containing sequences.

What if the certificate of analysis has no lot number?

Treat the certificate as unusable and request the lot-specific document before the material enters any experiment. A certificate exists to connect analytical data to one defined batch of material. Without the lot identifier, the document describes a batch that may have been synthesised years earlier by a different manufacturer. Reusing a single PDF across multiple batches is one of the most common documentation shortcuts in this market, and it is invisible unless you compare the certificate against the vial label directly.

What if the powder looks like a thin film rather than a pellet?

Do not assume degradation. Lyophilisation cake appearance varies with fill volume, vial geometry and the freeze-drying cycle used, and a thin film, a loose fluff or a compact pellet can all represent in-spec material. Appearance is a qualitative observation, not an assay. The questions that actually answer the concern are whether the mass spectrometry result matches the expected value and whether the HPLC trace shows a single dominant peak, both of which belong on the lot certificate.

What if a supplier only provides a purity percentage and no raw data?

Ask once for the chromatogram and the mass spectrometry trace, and treat refusal as a disqualifying answer. Any supplier running genuine third-party testing already holds those files, because the percentage is derived from them. A vendor who can quote a number but cannot produce the underlying trace is almost certainly repeating a figure supplied upstream rather than testing anything. Published certificates, like those on our COA page, exist precisely so this question never requires an email.

The Unglamorous Truth About Short Peptide Research

Here's the honest answer: the evidence base around Pinealon is thin. It is preclinical, it leans heavily on one research school, and independent replication in high-visibility journals is sparse. Anyone describing confirmed human benefits is running well ahead of what the published record will carry. That does not make the compound uninteresting as a research subject. It makes the marketing around it unreliable. The useful posture is to treat the literature as a starting hypothesis, treat the certificate as the only claim you can actually verify, and treat every outcome promise as a sales artefact rather than data.

Pinealon ends up being a documentation problem before it is ever a chemistry problem. Two vials of white powder look identical, cost roughly the same, and behave completely differently in an assay if one of them is a mislabelled sequence or a lot that absorbed moisture in a poorly sealed container. The chromatogram, the mass spectrometry trace and the lot number are the only parts of a purchase that can be checked by anyone other than the person selling it. All products are sold for laboratory research use only and are not for human consumption, and in a research setting, the paperwork is the product.

What is Pinealon's amino acid sequence, and how does it differ from other Khavinson bioregulators?

Pinealon is a synthetic tripeptide composed of glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg, often abbreviated EDR). It belongs to the family of short peptides developed within the Russian bioregulator research tradition, where low-molecular-weight sequences were derived conceptually from peptide fractions isolated from animal tissue extracts. The history and origins of this research line explain why so many of these compounds share two- to four-residue lengths and a heavy representation of acidic and basic side chains.

Structurally, Pinealon is distinguished from related sequences by its charge distribution: two acidic residues paired with a strongly basic arginine, giving the molecule a net charge profile that researchers have proposed is relevant to its interaction with polyanionic DNA. Other bioregulators in the same family substitute lysine, alanine, or tryptophan and are studied against different tissue targets. A side-by-side look at the bioregulator mechanism framework clarifies how sequence identity, rather than tissue of origin, is now the operative definition.

Laboratories frequently ask whether Pinealon is simply a renamed variant of another pineal-derived preparation; the naming and sequence distinctions are covered separately, as are broader structural comparisons across research peptides used in neurobiology work.

How is Pinealon proposed to reach cell nuclei and interact with DNA?

The most-discussed hypothesis for Pinealon is nuclear penetration followed by sequence-selective interaction with double-stranded DNA. Because the tripeptide is small, uncharged at neither extreme of pH, and lacks a bulky scaffold, proponents argue it can traverse membranes and the nuclear envelope without a dedicated transporter. Once inside, the acidic and basic residues are proposed to contact exposed bases in the major groove of specific promoter regions, altering transcription factor access. This is the central claim examined in the detailed mechanism literature.

Supporting work in this area is largely biophysical and cell-culture based, using techniques such as circular dichroism, gel-shift assays, and fluorescence-labeled peptide tracking. Reported downstream readouts include changes in transcript abundance for genes associated with antioxidant defense and apoptosis regulation, which are discussed under gene expression modulation and in the broader treatment of downstream cellular effects.

Important caveats apply. Short peptides are rapidly hydrolyzed by extracellular and cytosolic peptidases, so distinguishing an intact-peptide effect from an effect of liberated free amino acids remains a methodological challenge. Investigators tracking tissue fate should review the available metabolism and tissue distribution material before attributing nuclear activity to the intact tripeptide.

What does the animal literature on Pinealon cover compared with human studies?

The overwhelming majority of Pinealon-related publications are preclinical. Rodent models dominate, including hypoxia and hypobaric stress paradigms, prenatal hypoxia models assessing offspring behavior, and oxidative-stress challenges in cultured neurons. Reported endpoints typically include survival of neural cells, markers of lipid peroxidation, and performance on standard maze or avoidance tasks. The division between these rodent datasets and the much thinner human record is the subject of a dedicated breakdown on animal versus human research.

Human-subject literature exists mainly as small observational or open-label reports published in Russian-language geriatric and gerontology journals, often without blinding, placebo control, or pre-registration. Western databases index comparatively few of these, and translations vary in quality. Anyone surveying the field should treat the summary of cognitive research evidence as a map of what has been claimed rather than a consensus position.

Registered, adequately powered randomized trials remain scarce, which is why discussions of the current clinical trial landscape emphasize absence of evidence rather than evidence of absence. Several widely repeated statements about Pinealon trace back to secondary sources rather than primary data, a problem addressed directly in the myths-versus-literature comparison.

Why does Pinealon's short plasma half-life matter for experimental design?

Tripeptides composed of standard L-amino acids are substrates for ubiquitous aminopeptidases, carboxypeptidases, and endopeptidases present in plasma, interstitial fluid, and intracellular compartments. The practical consequence is a very short systemic residence time, usually discussed in minutes rather than hours. The implications for sampling schedules are laid out in the half-life overview and expanded in the pharmacokinetic research notes.

For bench planning, this has several effects. Terminal-sampling studies that collect material an hour after exposure may detect little or no parent compound, even if a biological signal is present. Assay design therefore often relies on LC-MS/MS with short collection intervals, stabilized collection tubes containing peptidase inhibitors, and immediate freezing of samples. Some groups instead measure downstream transcriptional or proteomic markers on the assumption that effects outlast the molecule itself.

This disconnect between exposure duration and observed effect duration is one of the more interesting open questions in the field, and it overlaps with the tissue metabolism literature. Teams framing a hypothesis around sustained activity should be explicit about whether they are testing the intact peptide, a fragment, or a secondary cascade, as discussed in the mechanisms and reported benefits summary.

How stable is lyophilized Pinealon during long-term storage?

Lyophilized short peptides are generally the most stable form available, and Pinealon follows the usual pattern. In a sealed vial under vacuum or inert headspace, with residual moisture controlled during the freeze-drying cycle, the solid material resists the hydrolysis and deamidation pathways that degrade peptides in aqueous environments. Standard laboratory practice is freezer storage, protection from light, and minimizing warm-cold transitions that drive condensation inside the vial. Handling specifics for the solid form are covered in the lyophilized powder handling guide.

The practical degradation risks are moisture ingress through a compromised stopper, repeated exposure to ambient humidity, and elevated temperature during transit. Glutamic and aspartic residues are the usual chemical weak points, with aspartate susceptible to isomerization and succinimide formation under unfavorable conditions. Periodic re-analysis by RP-HPLC, comparing retention time and peak area against the original certificate, is the usual way laboratories confirm that archived vials remain fit for use.

Fill quantity influences how often a vial is opened, which is why standard research vial formats matter for stability planning. Documentation of cold-chain handling is also one of the signals discussed in the guidance on evaluating whether a peptide supplier is legitimate.

Which biomarkers appear as endpoints in Pinealon-related research?

Published and proposed endpoints in Pinealon work cluster into a few categories. Oxidative-stress markers are the most common: malondialdehyde or other lipid peroxidation products, superoxide dismutase and catalase activity, and glutathione ratios in tissue homogenates. A second cluster involves apoptosis-related indicators, including caspase activity and Bcl-2 family transcript levels in neural tissue. A third involves circadian and neuroendocrine measures, typically melatonin or its urinary metabolite. These categories are organized in the biomarker reference breakdown.

Behavioral and electrophysiological endpoints appear alongside biochemical ones in rodent work: latency measures in avoidance tasks, EEG spectral analysis, and activity rhythm amplitude. Translating any of these to laboratory panels used in observational human research is imprecise, which is why discussions of laboratory panels examined before and after exposure periods stress interpretive limits rather than reference ranges.

Timeline expectations matter too. Transcriptional changes may be detectable within hours, while oxidative-stress markers often require repeated sampling across days to separate signal from assay noise. Observations about what measurable changes have actually been described and about reported timelines in cognitive endpoints are useful for setting realistic sampling windows in study design.

How does Pinealon compare with other short research peptides studied for neuroprotection?

Pinealon sits in a crowded category of low-molecular-weight peptides investigated for effects on neural tissue. The most direct comparators are other Khavinson-family sequences such as Epitalon (Ala-Glu-Asp-Gly) and Cortexin-derived preparations, which share the same theoretical framework of sequence-specific DNA interaction but differ in residue composition and claimed tissue specificity. A structured comparison appears in the research peptide comparison overview.

Outside that family, researchers often contrast Pinealon with Semax and Selank, both of which have substantially larger published literatures, documented receptor-adjacent mechanisms, and regulatory histories in their country of origin. Those peptides are longer, carry different stability profiles, and are typically studied against melanocortin or GABAergic/anxiolytic endpoints rather than transcriptional ones. A survey of research-grade alternatives outlines where each fits.

Comparison claims should be made cautiously. Differences in model systems, species, and endpoint selection make head-to-head potency statements unreliable, and very few studies have run parallel arms. The broader context of bioregulator peptides studied for brain protection explains the shared assumptions, while work on combinations with other peptides addresses the additive-effect questions that frequently follow comparison questions.

What does the literature say about Pinealon and sleep-wake regulation?

Interest in Pinealon's relationship to sleep derives from its association with pineal tissue research and the hypothesis that it influences melatonin-related signaling. The proposed mechanism is indirect: rather than acting as a melatonin receptor ligand, the tripeptide is described as modulating transcription in pinealocytes and related tissues, which could in principle affect enzymes in the serotonin-to-melatonin pathway such as AANAT. This proposed relationship is examined in the material on melatonin synthesis support.

Preclinical observations relevant to circadian biology include changes in locomotor rhythm amplitude and EEG architecture in rodent models, although methodology and reporting standards vary considerably across these publications. Discussions of sleep-wake cycle mechanisms note that rhythm amplitude and sleep continuity are distinct measures that are frequently conflated in secondary summaries.

Sleep fragmentation is a separate endpoint from total sleep duration, and the two respond differently to circadian versus homeostatic manipulations. The fragmented sleep mechanism discussion separates these constructs. Similarly, slow-wave activity is measured spectrally rather than by subjective report, a distinction emphasized in the deep sleep research notes. None of this literature constitutes evidence of clinical efficacy.

What confounders should be controlled in Pinealon experiments?

Short-peptide studies are unusually vulnerable to confounding because effect sizes are often small and endpoints are noisy. Co-exposures are the first category to control. Ethanol alters oxidative-stress markers, sleep architecture, and hepatic peptidase activity, any of which can mask or mimic a peptide signal; the overlap is reviewed in the ethanol co-exposure material. Caffeine and other methylxanthines affect adenosine signaling and circadian phase, making them relevant confounders in any sleep-related endpoint, as discussed in the caffeine interaction overview.

A second category is biochemical interference at the assay level. Buffer components, carrier proteins, and preservatives can suppress or enhance LC-MS/MS ionization or interfere with colorimetric oxidative-stress assays. Running matrix-matched calibration curves and solvent blanks addresses most of this.

Third, model-level variables: circadian timing of sampling, light cycle, ambient temperature, and housing density all shift the same markers Pinealon studies target. Failure to fix sampling time alone can generate apparent effects. Broader interaction considerations and documented safety and handling limitations are worth reviewing during protocol design so that control arms are specified before data collection rather than after.